FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308654817> ?p ?o ?g. }

• W4308654817 endingPage "345" @default.
• W4308654817 startingPage "338" @default.
• W4308654817 abstract "To analyze the 3-year outcomes in a broad population of patients starting VEGF inhibitors for central retinal vein occlusion (CRVO) in routine clinical practice.Observational database study.Overall, 527 treatment-naïve CRVO eyes that commenced VEGF inhibitors between December 1, 2010 and 2018 were tracked in the Fight Retinal Blindness! registry.Longitudinal models were used to plot changes in visual acuity (VA) and central subfield thickness (CST).Mean change in VA from baseline to 36 months, injections, visits, completion, switching, and suspensions of therapy > 180 days at the final review.Overall (527 eyes) mean VA change (95% confidence interval [CI]) was + 10 (7, 12) letters, 37% had final VA ≥ 70 and 30% ≤ 35 letters, mean CST changed -306 μm. Completers (257/527, 49%) had mean 36-month changes in VA and CST of + 12 letters and -324 μm with a median of 18 injections at 26 visits. The adjusted mean VA change was similar to each VEGF inhibitor (mean, + 11.4 letters) despite a greater reduction in CST with aflibercept (-310 μm) versus ranibizumab (-258 μm) versus bevacizumab (-216 μm; P < 0.001). Eyes with baseline VA that was trial-eligible (19-73 letters; 356/527, 68%) gained 7 letters, very poor (< 19 letters; 129/527, 24%) gained 22 letters, or very good (> 73 letters; 42/527, 8%) lost 7 letters. Switching (160/527, 30%) was most often to aflibercept (79 eyes). By using suspensions and discontinuation reasons, we identified similar proportions had ceased therapy (154/527, 29%) and were still receiving it at 36 months (165/527, 31%). Only 62/527 eyes (12%) had resolution of macular edema without treatment for > 6 months.Patients with CRVO that commenced VEGF inhibitors in routine care for whom follow-up was available had VA improvements of around 12 letters at 3 years, but with > 50% lost to follow-up, the VA outcome for the entire group was likely worse. The choice of VEGF inhibitor influenced CST but not VA outcomes. We estimated that around half of the eyes were still receiving injections after 36 months.Proprietary or commercial disclosure may be found after the references." @default.
• W4308654817 created "2022-11-13" @default.
• W4308654817 creator A5009775037 @default.
• W4308654817 creator A5019510374 @default.
• W4308654817 creator A5023996852 @default.
• W4308654817 creator A5028280746 @default.
• W4308654817 creator A5045091919 @default.
• W4308654817 creator A5051691422 @default.
• W4308654817 creator A5060316399 @default.
• W4308654817 creator A5061933063 @default.
• W4308654817 creator A5067855482 @default.
• W4308654817 creator A5072951845 @default.
• W4308654817 creator A5081717214 @default.
• W4308654817 creator A5083515958 @default.
• W4308654817 creator A5085397400 @default.
• W4308654817 creator A5087184887 @default.
• W4308654817 date "2023-04-01" @default.
• W4308654817 modified "2023-09-30" @default.
• W4308654817 title "Central Retinal Vein Occlusion 36-Month Outcomes with Anti-VEGF" @default.
• W4308654817 cites W1971399814 @default.
• W4308654817 cites W1976154023 @default.
• W4308654817 cites W1992527753 @default.
• W4308654817 cites W2034477424 @default.
• W4308654817 cites W2052204551 @default.
• W4308654817 cites W2128701654 @default.
• W4308654817 cites W2166985747 @default.
• W4308654817 cites W2172223254 @default.
• W4308654817 cites W2592892574 @default.
• W4308654817 cites W2612836720 @default.
• W4308654817 cites W2750848006 @default.
• W4308654817 cites W2897995397 @default.
• W4308654817 cites W2925601565 @default.
• W4308654817 cites W2931710213 @default.
• W4308654817 cites W2968480065 @default.
• W4308654817 cites W2971306116 @default.
• W4308654817 cites W2976285307 @default.
• W4308654817 cites W2979643225 @default.
• W4308654817 cites W3088013228 @default.
• W4308654817 cites W3133673296 @default.
• W4308654817 cites W3200955316 @default.
• W4308654817 cites W3206145898 @default.
• W4308654817 cites W4200505688 @default.
• W4308654817 cites W4235001346 @default.
• W4308654817 cites W4292229870 @default.
• W4308654817 doi "https://doi.org/10.1016/j.oret.2022.11.001" @default.
• W4308654817 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36371040" @default.
• W4308654817 hasPublicationYear "2023" @default.
• W4308654817 type Work @default.
• W4308654817 citedByCount "1" @default.
• W4308654817 countsByYear W43086548172023 @default.
• W4308654817 crossrefType "journal-article" @default.
• W4308654817 hasAuthorship W4308654817A5009775037 @default.
• W4308654817 hasAuthorship W4308654817A5019510374 @default.
• W4308654817 hasAuthorship W4308654817A5023996852 @default.
• W4308654817 hasAuthorship W4308654817A5028280746 @default.
• W4308654817 hasAuthorship W4308654817A5045091919 @default.
• W4308654817 hasAuthorship W4308654817A5051691422 @default.
• W4308654817 hasAuthorship W4308654817A5060316399 @default.
• W4308654817 hasAuthorship W4308654817A5061933063 @default.
• W4308654817 hasAuthorship W4308654817A5067855482 @default.
• W4308654817 hasAuthorship W4308654817A5072951845 @default.
• W4308654817 hasAuthorship W4308654817A5081717214 @default.
• W4308654817 hasAuthorship W4308654817A5083515958 @default.
• W4308654817 hasAuthorship W4308654817A5085397400 @default.
• W4308654817 hasAuthorship W4308654817A5087184887 @default.
• W4308654817 hasBestOaLocation W43086548171 @default.
• W4308654817 hasConcept C118487528 @default.
• W4308654817 hasConcept C126322002 @default.
• W4308654817 hasConcept C141071460 @default.
• W4308654817 hasConcept C2776694085 @default.
• W4308654817 hasConcept C2777802072 @default.
• W4308654817 hasConcept C2778257484 @default.
• W4308654817 hasConcept C2778715236 @default.
• W4308654817 hasConcept C2778749236 @default.
• W4308654817 hasConcept C2778844676 @default.
• W4308654817 hasConcept C2780347916 @default.
• W4308654817 hasConcept C2781100027 @default.
• W4308654817 hasConcept C2908647359 @default.
• W4308654817 hasConcept C44249647 @default.
• W4308654817 hasConcept C71924100 @default.
• W4308654817 hasConcept C99454951 @default.
• W4308654817 hasConceptScore W4308654817C118487528 @default.
• W4308654817 hasConceptScore W4308654817C126322002 @default.
• W4308654817 hasConceptScore W4308654817C141071460 @default.
• W4308654817 hasConceptScore W4308654817C2776694085 @default.
• W4308654817 hasConceptScore W4308654817C2777802072 @default.
• W4308654817 hasConceptScore W4308654817C2778257484 @default.
• W4308654817 hasConceptScore W4308654817C2778715236 @default.
• W4308654817 hasConceptScore W4308654817C2778749236 @default.
• W4308654817 hasConceptScore W4308654817C2778844676 @default.
• W4308654817 hasConceptScore W4308654817C2780347916 @default.
• W4308654817 hasConceptScore W4308654817C2781100027 @default.
• W4308654817 hasConceptScore W4308654817C2908647359 @default.
• W4308654817 hasConceptScore W4308654817C44249647 @default.
• W4308654817 hasConceptScore W4308654817C71924100 @default.
• W4308654817 hasConceptScore W4308654817C99454951 @default.
• W4308654817 hasIssue "4" @default.
• W4308654817 hasLocation W43086548171 @default.

• next